... ENG

SABCS 2024

SABCS 2024 - Dr. Edith A. Perez shares insights on the most anticipated abstracts and studies

Dr. Edith A. Perez, Professor Emeritus at Mayo Clinic, Chief Scientific Officer at oncoXchange, and an internationally recognized translational researcher and cancer specialist, previews SABCS 2024. She shares insights on the most anticipated abstracts and studies, highlighting exciting and potentially practice-changing results that could shape the future of breast cancer care.

SABCS 2024 -  Dr. Edith A. Perez shares insights on the most anticipated abstracts and studies

ESMO 2024

ESMO 2024: Dr. Tarek Hijal on Hypofractionated Radiotherapy in Breast Cancer

Dr. Tarek Hijal provides key insights from Day 3 of ESMO 2024, focusing on the latest developments in hypofractionated radiotherapy for breast cancer. He discusses significant findings from the Phase III HypoG-01 trial, led by Dr. Sofia Rivera from Gustave Roussy, France. Dr. Hijal explores how these results are poised to impact breast cancer treatment, particularly in optimizing radiotherapy approaches for better patient outcomes.

ESMO 2024: Dr. Tarek Hijal on Hypofractionated Radiotherapy in Breast Cancer

ESMO 2024 - Daily RECAP day 3

Dr. Jamil Asselah, along with guests Dr. Kim Ma and Dr. Paolo Tarantino, discuss the morning sessions focused on metastatic and early breast cancer. The panel recaps significant data including insights from the DETECT V trial, KEYNOTE 522, DESTINY-Breast12, and updates from the Natalee trial.

ESMO 2024 - Daily RECAP day 3

ESMO 2024: Dr. Cristina Saura: Key ESMO Findings on Breast Cancer Trials & Breastfeeding Safety

Dr. Cristina Saura highlights three key messages from the ESMO 2024 meeting, focusing on significant advancements in breast cancer research. First, the results of the DESTINY-Breast12 trial showcased new treatment options for advanced breast cancer. Second, the ICARUS-BREAST01 study provided further insights into innovative therapeutic approaches. Lastly, she emphasized two groundbreaking international studies that confirmed breastfeeding after breast cancer treatment does not increase the risk of recurrence or new cancers, marking an important step for young survivors seeking safe breastfeeding options.

ESMO 2024: Dr. Cristina Saura: Key ESMO Findings on Breast Cancer Trials & Breastfeeding Safety

ESMO 2024 - Daily RECAP day 2

In this DailyRECAP for September 15th, Dr. Jamil Asselah returns for a second overview of the day’s breast cancer sessions from ESMO 2024, joined by Dr. Rami Younan and Dr. Kim Ma. They focus on key insights from the Presidential Symposium and practice-changing trials.

ESMO 2024 - Daily RECAP day 2

ASCO 2024

ASCO 2024 - Daily RECAP day2

Join Dr. Jamil Asselah and Dr. Kim Ma, along with Dr. Véronique Diéras, as they review the day's highlights with a special focus on the positive findings from the DESTINY-Breast06 trial. They will discuss how these results are set to impact clinical practice, particularly for patients with HER2-ultralow breast cancer, and delve into all aspects of T-DXd in treatment strategies.

ASCO 2024 - Daily RECAP day2

ASCO 2024: Daily RECAP day 1 with Drs. Asselah and Ma

Join Drs. Asselah and Ma as they review the key takeaways from Day 1 of ASCO. They delve into hormone-positive disease, discuss notable abstracts, and provide insights on the Flex trial registry. Hear about Dr. Grace Choong’s research from Mayo Clinic on endocrine therapy for ER-low breast cancer patients. Stay tuned for what to expect in the days ahead at the conference.

ASCO 2024: Daily RECAP day 1 with Drs. Asselah and Ma

ASCO 2024 : Global Speaker Series with Dr. Conte

Join Dr. Pier Franco Conte as he discusses the A-BRAVE trial, a Phase III randomized study exploring the use of avelumab in early triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy or those at high risk following primary surgery and adjuvant chemotherapy.

ASCO 2024 : Global Speaker Series with Dr. Conte

ASCO 2024 : Global Speaker Series with Dr. Santa Maria

Join Dr. Santa Maria as he discusses his current project exploring the use of chemotherapy combined with immunotherapy in patients with stage 2 and 3 triple-negative breast cancer. Learn how early PET scan changes are being used to identify patients who achieve a complete pathologic response earlier in the treatment process.

ASCO 2024 : Global Speaker Series with Dr. Santa Maria

CLINICAL IMPACT Series

Dr. Tarantino - DESTINY BREAST

SABCS 2023

SABCS 2023 : Global Speaker Series Dr. Peter Schmid

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study

SABCS 2023 : Global Speaker Series Dr. Peter Schmid

SABCS 2023 : Global Speaker Series Dr. Anne May

Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study

SABCS 2023 : Global Speaker Series Dr. Anne May

SABCS 2023 : MedTalk Dr. Mark Basik

Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor

SABCS 2023 : MedTalk Dr. Mark Basik

SABCS 2022

ESMO 2022

ASCO 2022

AI Series

AACR 2022

COVID Impact

OICR Series

SABCS 2021

ESMO 2021

ASCO 2021

SABCS 2020

Processes in cancer

All Editorial Videos

SABCS 2024 - Dr. Edith A. Perez shares insights on the most anticipated abstracts and studies

Dr. Edith A. Perez, Professor Emeritus at Mayo Clinic, Chief Scientific Officer at oncoXchange, and an internationally recognized translational researcher and cancer specialist, previews SABCS 2024. She shares insights on the most anticipated abstracts and studies, highlighting exciting and potentially practice-changing results that could shape the future of breast cancer care.

SABCS 2024 -  Dr. Edith A. Perez shares insights on the most anticipated abstracts and studies

ESMO 2024: Dr. Tarek Hijal on Hypofractionated Radiotherapy in Breast Cancer

Dr. Tarek Hijal provides key insights from Day 3 of ESMO 2024, focusing on the latest developments in hypofractionated radiotherapy for breast cancer. He discusses significant findings from the Phase III HypoG-01 trial, led by Dr. Sofia Rivera from Gustave Roussy, France. Dr. Hijal explores how these results are poised to impact breast cancer treatment, particularly in optimizing radiotherapy approaches for better patient outcomes.

ESMO 2024: Dr. Tarek Hijal on Hypofractionated Radiotherapy in Breast Cancer

ESMO 2024 - Daily RECAP day 3

Dr. Jamil Asselah, along with guests Dr. Kim Ma and Dr. Paolo Tarantino, discuss the morning sessions focused on metastatic and early breast cancer. The panel recaps significant data including insights from the DETECT V trial, KEYNOTE 522, DESTINY-Breast12, and updates from the Natalee trial.

ESMO 2024 - Daily RECAP day 3

ESMO 2024: Dr. Cristina Saura: Key ESMO Findings on Breast Cancer Trials & Breastfeeding Safety

Dr. Cristina Saura highlights three key messages from the ESMO 2024 meeting, focusing on significant advancements in breast cancer research. First, the results of the DESTINY-Breast12 trial showcased new treatment options for advanced breast cancer. Second, the ICARUS-BREAST01 study provided further insights into innovative therapeutic approaches. Lastly, she emphasized two groundbreaking international studies that confirmed breastfeeding after breast cancer treatment does not increase the risk of recurrence or new cancers, marking an important step for young survivors seeking safe breastfeeding options.

ESMO 2024: Dr. Cristina Saura: Key ESMO Findings on Breast Cancer Trials & Breastfeeding Safety

ESMO 2024 - Daily RECAP day 2

In this DailyRECAP for September 15th, Dr. Jamil Asselah returns for a second overview of the day’s breast cancer sessions from ESMO 2024, joined by Dr. Rami Younan and Dr. Kim Ma. They focus on key insights from the Presidential Symposium and practice-changing trials.

ESMO 2024 - Daily RECAP day 2

ASCO 2024 - Daily RECAP day2

Join Dr. Jamil Asselah and Dr. Kim Ma, along with Dr. Véronique Diéras, as they review the day's highlights with a special focus on the positive findings from the DESTINY-Breast06 trial. They will discuss how these results are set to impact clinical practice, particularly for patients with HER2-ultralow breast cancer, and delve into all aspects of T-DXd in treatment strategies.

ASCO 2024 - Daily RECAP day2

ASCO 2024: Daily RECAP day 1 with Drs. Asselah and Ma

Join Drs. Asselah and Ma as they review the key takeaways from Day 1 of ASCO. They delve into hormone-positive disease, discuss notable abstracts, and provide insights on the Flex trial registry. Hear about Dr. Grace Choong’s research from Mayo Clinic on endocrine therapy for ER-low breast cancer patients. Stay tuned for what to expect in the days ahead at the conference.

ASCO 2024: Daily RECAP day 1 with Drs. Asselah and Ma

ASCO 2024 : Global Speaker Series with Dr. Conte

Join Dr. Pier Franco Conte as he discusses the A-BRAVE trial, a Phase III randomized study exploring the use of avelumab in early triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy or those at high risk following primary surgery and adjuvant chemotherapy.

ASCO 2024 : Global Speaker Series with Dr. Conte

ASCO 2024 : Global Speaker Series with Dr. Santa Maria

Join Dr. Santa Maria as he discusses his current project exploring the use of chemotherapy combined with immunotherapy in patients with stage 2 and 3 triple-negative breast cancer. Learn how early PET scan changes are being used to identify patients who achieve a complete pathologic response earlier in the treatment process.

ASCO 2024 : Global Speaker Series with Dr. Santa Maria

SABCS 2023 : Global Speaker Series Dr. Peter Schmid

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study

SABCS 2023 : Global Speaker Series Dr. Peter Schmid

SABCS 2023 : Global Speaker Series Dr. Anne May

Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study

SABCS 2023 : Global Speaker Series Dr. Anne May

SABCS 2023 : MedTalk Dr. Mark Basik

Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor

SABCS 2023 : MedTalk Dr. Mark Basik